Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Clinical trial NCT06496048 · RECRUITING

Trial details

NCT number: NCT06496048
Sponsor: Luye Pharma Group Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsed Small Cell Lung Cancer

Start date: 2024-09-14
Primary completion: 2027-12-31
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.